Borui Pharmaceuticals: The new drug application for the weight loss indication of BGM0504 injection, independently developed by its wholly-owned subsidiary Borui Pharmaceutical Co., Ltd., has been accepted by the Center for Drug Evaluation of the Nat

2026-06-11

Borui Pharmaceuticals: The new drug application for the weight loss indication of BGM0504 injection, independently developed by its wholly-owned subsidiary Borui Pharmaceutical Co., Ltd., has been accepted by the Center for Drug Evaluation of the National Medical Products Administration.